Menu

UK to Legalize Medicinal Cannabis

Patients will be able to access the drug with a prescription, and there are no plans to allow for recreational use.

Jul 27, 2018
Catherine Offord

Doctors in the UK will be able to prescribe medicinal cannabis to patients starting in the fall of this year, according to a government announcement made yesterday (July 26). The move follows national debate over high-profile cases in which children with severe epilepsy were first denied, then allowed access to cannabis oil shown to ease the symptoms of the condition.

“Recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory,” Interior Minister Sajid Javid told reporters yesterday, according to Reuters. “Following advice from two sets of independent advisers, I have taken the decision to reschedule cannabis-derived medicinal products—meaning they will be available on prescription.”

Until now, cannabis has been considered a Schedule 1 substance, a legal classification that means the plant can be used by researchers with a license, but is not thought to have any therapeutic value. Yesterday’s announcement indicates that cannabis-derived products intended for medicinal use will now be classified as Schedule 2, allowing them to be prescribed directly to patients by specialist physicians.

See “Marijuana Research Still Stymied by Federal Laws

Before autumn, the government will clarify which types of products will meet the definition of medicinal. In the interim, “clinicians may still apply to the Home Office Expert Panel should they wish to use a cannabis-based medicine in the treatment of a patient,” a Home Office spokesperson told reporters, according to BBC News.

Karen Gray, a woman whose child suffers from epilepsy and who has campaigned for the legalization of cannabis for medicinal use, tells The Independent that the decision is a victory for those seeking treatment. “It’s really going to help children out there, so it’s brilliant news,” she says. “There are lots of kids out there who aren’t getting this help and hopefully now they will.”

Mike Barnes, a physician at neurological rehabilitation specialist Christchurch Group who secured access to cannabis oil for a child with epilepsy earlier this year, tells The Guardian that he hopes the rules won’t be “too restrictive, but sensibly open up the way to make good quality, safe cannabis available on prescription.”

Other countries that have already allowed medical marijuana include Australia, Germany, and Peru, along with some states in the US. Recreational use is currently fully legalized in Uruguay and, as of this June, Canada.

See “Canada Could Come to the Fore in Cannabis Research

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.